Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment

Clinical and Experimental Immunology

Volumn 161, Issue 1, 2010, Pages 134-141

  Barbai, V H ^a   Ujhelyi, E ^a   Szlavik J ^a   Vietorisz, I ^a   Varga, L ^b   Fey, E ^a   Fust G ^b   Banhegyi D ^a  

^a Fovarosi Onkormanyzat Egyesitett Szent Istvan Es Szent Laszlo Korhaz ^*  (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Acute phase protein; HIV infection; Interleukin 2

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 2HS GLYCOPROTEIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C9; D DIMER; GLYCOPROTEIN; PROLEUKINE; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; TREATMENT RESPONSE; VIRUS LOAD;

ACUTE-PHASE PROTEINS; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; RECOMBINANT PROTEINS;

EID: 77953254711     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04145.x     Document Type: Article

References (39)

1. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988 240 : 1169 1176.
2. Youle M, Emery S, Fisher M et al. A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: The UK-Vanguard Study. PLoS Clin Trials 2006 1 : e3.
3. Vogler MA, Teppler H, Gelman R et al. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr 2004 36 : 576 587.
4. Emery S, Abrams DI, Cooper DA et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002 23 : 198 220.
5. Durier C, Capitant C, Lascaux AS et al. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). Aids 2007 21 : 1887 1897.
6. Arduino RC, Nannini EC, Rodriguez-Barradas M et al. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Clin Infect Dis 2004 39 : 115 122.
7. 3: Primary results of the SILCAAT study. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 2009.
8. 3: Primary results of the ESPRIT study. 16th Conference on Retroviruses and Opportunistic Infection. Montreal, Canada, 2009.
9. Fortis C, Soldini L, Ghezzi S et al. Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2. AIDS Res Hum Retroviruses 2002 18 : 491 499.
10. Mier JW, Vachino G, van der Meer JW et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988 8 : 426 436.
11. Heaton KM, Ju G, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res 1993 53 : 2597 2602.
12. Deehan DJ, Heys SD, Simpson W, Herriot R, Broom J, Eremin O. Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clin Exp Immunol 1994 95 : 366 372.
13. Baars JW, de Boer JP, Wagstaff J et al. Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia. Br J Haematol 1992 82 : 295 301.
14. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 1982 389 : 39 48.
15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999 340 : 448 454.
16. Jahoor F, Gazzard B, Phillips G et al. The acute-phase protein response to human immunodeficiency virus infection in human subjects. Am J Physiol 1999 276 : E1092 8.
17. Lau B, Sharrett AR, Kingsley LA et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006 166 : 64 70.
18. Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr 2003 32 : 210 214.
19. Henry K, Kitch D, Dube M et al. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. Aids 2004 18 : 2434 2437.
20. Chaudhary M, Kashyap B, Gautam H, Saini S, Bhalla P. Role of C-reactive protein in HIV infection: A pilot study. Viral Immunol 2008 21 : 263 266.
21. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002 185 : 456 462.
22. Madden E, Lee G, Kotler DP et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. Aids 2008 22 : 707 715.
23. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999 100 : 700 705.
24. Kuller LH, Tracy R, Belloso W et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008 5 : e203.
25. Gunther K, Dhlamini B. d-Dimer levels are markedly raised in HIV-related thrombotic thrombocytopenic purpura. Aids 2007 21 : 1063 1064.
26. Senaldi G, Peakman M, McManus T, Davies ET, Tee DE, Vergani D. Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity. J Infect Dis 1990 162 : 1227 1232.
27. Robinson WE. Mechanism for complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors. Viral Immunol 2006 19 : 434 447.
28. Prohaszka Z, Nemes J, Hidvegi T et al. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. Aids 1997 11 : 949 958.
29. Cleve H, Weidinger S, Gurtler LG, Deinhardt F. AIDS: no association with the genetic systems GC (d-binding protein), ORM (orosomucoid = alpha-1-acid glycoprotein), and A2HS (alpha-2-HS-glycoprotein). Infection 1988 16 : 31 5.
30. Kalabay L, Jakab L, Prohaszka Z et al. Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol 2002 14 : 389 394.
31. Porter BO, Shen J, Kovacs JA et al. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and d-dimer that are not associated with plasma HIV-RNA levels. Aids 2009 23 : 2015 2019.
32. Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965 2 : 235 254.
33. [Anonymous]. 1994 revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 1994 43 (RR-3 1 21.
34. Hack CE, Ogilvie AC, Eisele B, Eerenberg AJ, Wagstaff J, Thijs LG. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intens Care Med 1993 19 (Suppl. 1 S19 S28.
35. Ogilvie AC, Baars JW, Eerenberg AJ et al. A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2. Br J Cancer 1994 69 : 596 598.
36. Volanakis JE. Complement activation by C-reactive protein complexes. Ann NY Acad Sci 1982 389 : 235 250.
37. 3: CPCRA 059. J Acquir Immune Defic Syndr 2002 29 : 221 231.
38. Davey RT Jr., Murphy RL, Graziano FM et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA 2000 284 : 183 189.
39. Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996 93 : 10405 10410.